Chemours
CC · NYSE · Materials · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$5.8B
Net margin
-6.6%
ROE
-68.2%
Revenue CAGR (2y)
-2.2%
EPS (FY2025)
-2.57
Net profit (FY2025)
$-386.0M
Ask MarketChacha about CC
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Aug 4, 2026
No specific catalyst identified in recent filings or credible news coverage; the stock rose ahead of its Q2 2026 earnings release scheduled after market close.
· confidence: low - Jul 23, 2026
No specific company catalyst or filing identified for the decline; shares pulled back with no clear driver from recent news or results, consistent with sector/market movement after prior gains.
· confidence: low
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $5.8B | $-386.0M | -2.57 | -6.6% | -68.2% |
| FY2024 | $5.8B | $69.0M | 0.46 | 1.2% | 12.1% |
| FY2023 | $6.1B | $-253.0M | -1.70 | -4.2% | -35.1% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $1.6B | $-274.0M | -1.81 | -17.2% |
| 2026Q1 | $1.4B | $-29.0M | -0.19 | -2.1% |
| 2025Q4 | $1.3B | $-47.0M | -0.31 | -3.5% |
| 2025Q3 | $1.5B | $46.0M | 0.31 | 3.1% |
| 2025Q2 | $1.6B | $-380.0M | -2.53 | -23.5% |
| 2025Q1 | $1.4B | $-5.0M | -0.03 | -0.4% |
| 2024Q4 | $1.4B | $-11.0M | -0.08 | -0.8% |
| 2024Q3 | $1.5B | $-32.0M | -0.22 | -2.1% |
| 2024Q2 | $1.6B | $60.0M | 0.39 | 3.9% |
| 2024Q1 | $1.4B | $54.0M | 0.36 | 4.0% |
| 2023Q4 | $1.4B | $-18.0M | -0.12 | -1.3% |
| 2023Q3 | $1.5B | $12.0M | 0.08 | 0.8% |
| 2023Q2 | $1.7B | $-376.0M | -2.52 | -22.7% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/5/2026
- SEC8/4/2026material
- SEC6/24/2026material
- SEC5/5/2026material
- SEC5/5/2026
- SEC4/30/2026material
- SEC3/12/2026material
- SEC2/26/2026material
- SEC2/24/2026
- SEC2/19/2026material
- SEC1/16/2026material
2025
- SEC11/6/2025material
- SEC11/6/2025
- SEC10/31/2025material
- SEC10/16/2025material
- SEC9/3/2025material
- SEC8/29/2025material
- SEC8/5/2025material
- SEC8/5/2025
- SEC8/4/2025material
In the news
- Chemours president Martinko buys $30,008 in company stock By Investing.comInvesting.com South Africa · 8/16/2026
- Chemours director Alister Cowan buys $203,060 of company stock By Investing.comInvesting.com Australia · 8/16/2026
- Chemours (NYSE:CC) CEO Acquires $50,501.10 in StockMarketBeat · 8/13/2026
- Chemours Co (CC) executive increases holdings with 1,935-share open-market buyStock Titan · 8/13/2026
- Chemours (CC) Stock Stays Cheap On A 48% Three Year SlumpYahoo Finance · 8/13/2026
- JPMorgan Chase & Co. Cuts Chemours (NYSE:CC) Price Target to $15.00MarketBeat · 8/13/2026
- Chemours (CC) On Results And Data Center Push Has Value Back In Focussimplywall.st · 8/13/2026
- BMO Capital Markets Has Lowered Expectations for Chemours (NYSE:CC) Stock PriceMarketBeat · 8/13/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.